Amended Statement of Ownership (sc 13g/a)
09 February 2016 - 9:29AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. 1)*
TapImmune
Inc.
(Name
of Issuer)
Common
Stock, $0.001 par value
(Title of Class of Securities)
876033309
(CUSIP Number)
December
31, 2015
(Date of event which requires filing of
this statement)
Check the appropriate box to designate
the rule pursuant to which this Schedule 13G is filed:
|
o | | Rule 13d-1(b) |
|
x | | Rule 13d-1(c) |
|
o | | Rule 13d-1(d) |
(Page 1 of 11 Pages)
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1 |
NAMES OF REPORTING PERSONS
Iroquois Capital Management L.L.C. |
|
|
2 |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP |
(a) o (b) o |
|
|
|
|
|
|
|
3 |
SEC USE ONLY |
|
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING
POWER |
|
|
6 |
SHARED VOTING POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
7 |
SOLE DISPOSITIVE POWER |
|
|
8 |
SHARED DISPOSITIVE POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
o |
|
|
|
|
|
|
|
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (See Item 4)* |
|
|
12 |
TYPE OF REPORTING
PERSON
OO |
* As more fully described in Item 4, the Series A, D and E Warrants
are subject to a 4.9% blocker and the Series C Warrants are subject to a 9.9% blocker and the percentage set forth in row (11)
gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show
the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect
to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving
effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).
1 |
NAMES OF REPORTING PERSONS
Joshua Silverman |
|
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) o (b) o |
|
|
|
|
|
|
|
3 |
SEC USE ONLY |
|
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America |
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING
POWER |
|
|
6 |
SHARED VOTING POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
7 |
SOLE DISPOSITIVE POWER |
|
|
8 |
SHARED DISPOSITIVE POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
o |
|
|
|
|
|
|
|
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (See Item 4)* |
|
|
12 |
TYPE OF REPORTING PERSON
IN; HC |
* As more fully described in Item 4, the Series A, D and E Warrants
are subject to a 4.9% blocker and the Series C Warrants are subject to a 9.9% blocker and the percentage set forth in row (11)
gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show
the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect
to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving
effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).
1 |
NAMES OF REPORTING PERSONS
Richard Abbe |
|
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) o (b) o |
|
|
|
|
|
|
|
3 |
SEC USE ONLY |
|
|
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America |
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
979,990 shares of Common Stock
1,249,990 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
499,995 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
6 |
SHARED VOTING POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
7 |
SOLE DISPOSITIVE POWER
979,990 shares of Common Stock
1,249,990 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
499,995 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
8 |
SHARED DISPOSITIVE POWER
2,231,124 shares of Common Stock
3,750,000 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,500,000 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,211,114 shares of Common Stock
4,999,990 shares of Common Stock issuable upon exercise of Series A, D and E Warrants (See Item 4)*
2,999,995 shares of Common Stock issuable upon exercise of Series C Warrants (See Item 4)* |
|
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
o |
|
|
|
|
|
|
|
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (See Item 4)* |
|
|
12 |
TYPE OF REPORTING
PERSON IN; HC |
* As more fully described in Item 4, the Series A, D and E Warrants
are subject to a 4.9% blocker and the Series C Warrants are subject to a 9.9% blocker and the percentage set forth in row (11)
gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show
the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect
to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving
effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).
This Amendment No. 1 (this “Amendment”)
amends the statement on Schedule 13G filed on March 13, 2015 (the “Original Schedule 13G”) with respect to the Common
Stock, $0.001 par value (the “Common Stock”) of TapImmune Inc., a Nevada corporation (the “Company”). Capitalized
terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment
amends and restates Item 4 in its entirety as set forth below.
|
The information as of the date of the event which requires filing
of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person
hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover
page for each Reporting Person is based on 64,618,762 shares of Common Stock issued and outstanding as of November 16, 2015, as
represented in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November
16, 2015, an additional 5,712,000 shares of Common Stock subsequently issued, as indicated in the Current Report on Form 8-K filed
with the Securities and Exchange Commission on December 11, 2015, and assumes the exercise of the reported warrants (the “Reported
Warrants”) subject to the Blockers (as defined below).
Pursuant to the terms of the Reported Warrants, the Reporting
Persons cannot exercise (i) any of the Reported Warrants that are Series A, Series D or Series E Warrants if the Reporting Persons
would beneficially own, after any such exercise, more than 4.9% of the outstanding shares of Common Stock or (ii) any of the Reported
Warrants that are Series C Warrants if the Reporting Persons would beneficially own, after any such exercise, more than 9.9% of
the outstanding shares of Common Stock (the applicable “Blockers”), and the percentage set forth in Row 11 of the cover
page for each Reporting Person gives effect to the applicable Blockers. Consequently, as of the date of the event which requires
the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the applicable
Blockers.
Mr. Abbe and Mr. Silverman are the members of Iroquois who have
the authority and responsibility for the investments made on behalf of the Fund. As such, Mr. Abbe and Mr. Silverman may be deemed
to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the applicable
Blockers) held by, the Fund. In addition, by virtue of his position as a custodian or trustee of certain Accounts (The Merav Abbe
Irrevocable Trust, The Samantha Abbe Irrevocable Trust, The Talia Abbe Irrevocable Trust and The Bennett Abbe Irrevocable Trust),
Mr. Abbe may be deemed to be the beneficial owner of the shares of Common Stock held by, and underlying the Reported Warrants (subject
to the applicable Blockers) held by, such Accounts. The foregoing should not be construed in and of itself as an admission by any
Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting
Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary
interest therein.
|
Each of the Reporting Persons hereby makes the following certification:
By signing below each Reporting Person certifies that, to the
best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with
the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 8, 2016
|
IROQUOIS CAPITAL MANAGEMENT L.L.C. |
|
|
|
|
By: |
/s/ Joshua Silverman |
|
|
Joshua Silverman, Authorized Signatory |
|
|
|
|
|
/s/ Joshua Silverman |
|
|
Joshua Silverman |
|
|
|
|
|
/s/ Richard Abbe |
|
|
Richard Abbe |
|
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Sep 2024 to Oct 2024
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Oct 2023 to Oct 2024